Zinc/PSA Ratio as a Novel Biomarker for Prostate Cancer Detection

Prostate Cancer Detection Clinical Trial

Official title:

Zinc/PSA Ratio as a Novel Biomarker for Prostate Cancer Detection

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02013180
• Other study ID #: Zinc/PSA
• Status: Completed
• Start date: July 2012
• Est. completion date: January 2017

Study information

• Verified date: November 2017
• Source: Bagcilar Training and Research Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Although Prostate Specific Antigen (PSA) is a useful marker for early detection of the prostate cancer, its specivity is not sufficient. Several PSA variations were defined in order to increase the specivity of the test, but they aren't much more effective than the PSA alone for detection of disease.

In older studies reported that, serum and prostatic tissue zinc levels decreased in prostat cancer disease.

In our study we aimed to establish the utility of serum zinc, PSA, free PSA/PSA (fPSA/tPSA), zinc/PSA, levels for early detection of the prostate cancer.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 480
• Est. completion date: January 2017
• Est. primary completion date: January 2013
• Accepts healthy volunteers: No
• Gender: Male
• Age group: N/A and older

Eligibility

Inclusion Criteria:

Patients with LUTS and elevated serum PSA levels and/or suspicious rectal examination

Exclusion Criteria:

usage of zinc included drugs, older prostatic operations, older prostatic radiotherapy, older prostatic biopsies, chronic rectal diseases (anal fissure, hemorrhoid, etc..), PIN(prostatic intraepithelial neoplasia) and ASAP(atypical small acinar proliferation) in pathologic evaluation.

Related Conditions & MeSH terms

• Prostate Cancer Detection
• Prostatic Neoplasms

Locations

Country	Name	City	State
Turkey	Bagcilar Training and Research Hospital-Depertmant of Urology	Istanbul	Bagcilar

Sponsors (1)

Lead Sponsor	Collaborator
Bagcilar Training and Research Hospital

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assesment of Serum Zinc/PSA Ratio in Patients With Prostate Cancer and Benign Prostatic Diseases	Does the zinc/PSA ratio show statistically signifacant difference in patients with prostate cancer?	measurement of serum zinc and PSA levels are performed prior to transrectal prostat biopsy; pathologic evaluation of biopsy specimens are performed within 2-3 weeks